Gene silencing in severe systemic inflammation

Area of Science:

• Critical Care Medicine
• Molecular Biology
• Immunology

Background:

• Severe systemic inflammation, including systemic inflammatory response syndrome (SIRS), sepsis, and septic shock, involves complex gene expression changes.
• Localized inflammatory processes, such as rheumatoid arthritis, exhibit different gene expression patterns compared to systemic inflammation.
• Understanding gene reprogramming in inflammation is crucial for developing novel therapeutic strategies.

Purpose of the Study:

• To appraise the concept of gene expression reprogramming in inflammatory diseases.
• To emphasize the role of gene silencing in severe systemic inflammation and the SIRS continuum.
• To explore the clinical and basic science context of gene silencing during SIRS.

Main Methods:

• Review and synthesis of current literature on gene reprogramming in inflammatory diseases.
• Analysis of gene silencing mechanisms, including the "nuclear factor-kappaB paradox" and epigenetic modifications.
• Discussion of the potential clinical implications of gene silencing compartmentalization.

Main Results:

• Gene reprogramming that silences acute proinflammatory genes is a key feature of severe systemic inflammation (SIRS continuum).
• This silencing is not observed in localized inflammatory conditions like rheumatoid arthritis.
• Epigenetic mechanisms involving nucleosome modifications and RelB expression contribute to gene silencing.

Conclusions:

• Emergent understanding of gene silencing in SIRS provides a novel framework for treatment development.
• Targeting gene reprogramming offers a potential therapeutic avenue for critical care conditions characterized by severe systemic inflammation.
• Further research into the compartmentalization of gene silencing may reveal specific therapeutic targets.